Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 3/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | WNT3 | P56703 | 1/20 | 0.31 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797226 | 0.90 | DGAT1 (0.42) | F2RL1DGAT1RBP4ERN1IL1B | |
| SCHEMBL3787166 | 0.89 | SCN9A (0.40) | SCN9AF2RL1DGAT1PIK3CDPIK3CA | |
| SCHEMBL3791832 | 0.88 | F2RL1 (0.40) | SCN9AF2RL1DGAT1 | |
| SCHEMBL3790496 | 0.86 | SCN9A (0.34) | SCN9AF2RL1HRH3ERN1CCR1 | |
| SCHEMBL13228841 | 0.86 | SCN9A (0.34) | SCN9AF2RL1HRH3ERN1CCR1 | |
| SCHEMBL3788826 | 0.76 | ERN1 (0.35) | ERN1 | |
| SCHEMBL3687228 | 0.76 | ERN1 (0.36) | SCN9ARBP4ERN1 | |
| SCHEMBL1583795 | 0.76 | ERN1 (0.43) | ERN1 | |
| SCHEMBL3789230 | 0.76 | ITGB2 (0.35) | DGAT1ERN1PIK3CA | |
| SCHEMBL13228818 | 0.75 | P2RX7 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | SCN9A 2892/4885F2RL1 4595/4885DGAT1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.